Lagos State government has reaffirmed its commitment to safeguarding children from vaccine-preventable diseases and improving child survival outcomes across the state.

Wife of the governor, Dr Claudiana Ibijoke Sanwo-Olu, stated this during the introduction ceremony of the Measles–Rubella (MR) vaccine into the state’s Routine Immunisation Programme.
‎
Representing Sanwo-Olu, wife of the Deputy Governor, Mrs Oluremi Hamzat, described the introduction of the MR vaccine as a clear reflection of the vision and priorities of the Babajide Olusola Sanwo-Olu administration under the T.H.E.M.E.S+ Agenda.

She noted that Health, Human Capital Development, Social Inclusion, and Governance remain critical pillars for building a prosperous and inclusive Lagos.
‎
‎Mrs Sanwo-Olu stated that the current administration has made unprecedented investments in the health sector, leading to significant improvements in maternal and child health indices, with a strong emphasis on Primary Health Care as the foundation of a resilient and equitable health system.

According to her, the introduction of the MR vaccine is a strategic and timely intervention aimed at eliminating measles and rubella while preventing lifelong disabilities among children.
‎ ‎
Speaking at the flag-off ceremony, the Special Adviser to the Governor on Health, Dr Kemi Ogunyemi, also noted that integrating the Measles–Rubella vaccine into routine immunisation is a critical step towards securing the future of children.

“No child in Lagos should suffer or die from diseases that are preventable. This initiative underscores our administration’s unwavering commitment to child health, family well-being, and the strengthening of primary health care as the bedrock of a healthy society,” Ogunyemi stated.‎
‎
Speaking on the significance and scope of the initiative, the Permanent Secretary, Lagos State Primary Health Care Board, Dr Ibrahim Akinwunmi Mustafa, explained that the introduction of the MR vaccine marks a shift from reactive outbreak response to sustained disease prevention.

He disclosed that over 10.4 million children, aged nine months to 14 years, will be reached during the initial mass vaccination phase, after which the vaccine will be fully integrated into routine immunisation services at nine months (MR1) and 15 months (MR2).